Skip to content

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again

      EMEA/Our innovation /Focus areas/Oncology /Prostate cancer

      Prostate cancer

      Prostate cancer is the most common cancer in men across Europe.[1] In 2020, across Europe, approximately 473,000 men were diagnosed with prostate cancer.[1] There is a clear need for diagnostic and/or prognostic tools that facilitate personalised prostate cancer treatment, so that one day a prostate cancer diagnosis will be less frightening for patients to hear, and less distressing for healthcare professionals to say and act upon.[2]

      We are leaders in prostate cancer, and are dedicated to helping delay disease progression.
      istock-995420532.jpg
      Our heritage in prostate cancer
      At Johnson & Johnson Oncology, we have a legacy of innovation in prostate cancer treatment. We’ve been actively engaged in prostate cancer care for a decade. From our first approval in 2011, we have continued to build on the insights from our clinical research, leading us to five approved indications in prostate cancer.
      JJ_Photo_Micro Onc PC-3 human prostate cancer cells_Shutterstock_425734612_1Star.jpg
      Our goal
      Building on this heritage, we are striving to ensure we can bring the right treatment, to the right patient, at the right time across the entire prostate cancer journey.

      We are exploring innovative approaches, such as using novel intermediate endpoints, which could transform the entire trajectory of cancer, and get one step closer to a cure.[3],[4]
      Grandfather and grandson taking a break in mountains, giving high five and eating sandwiches
      Our dedication to improving quality of life
      While extending life remains a key focus, patient quality of life is always at the forefront of our minds. For us, helping to give patients more valuable time with their loved ones, to enjoy more of life’s meaningful moments, is what makes our work truly worthwhile.
      More from Oncology at Johnson & Johnson Innovative Medicine EMEA

      References

      [1] IARC. Online analysis table. Available at: https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=cancer&mode_po.... Accessed January 2023.
      [2] Smith-Palmer et al. Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada. BMC Urology. 2019 19, 19.
      [3] Hait, W.N. et al. Moving upstream in anticancer drug development. Nat Rev. 2018; 18: 159-160
      [4] Delgado, A, et al. Clinical endpoints in oncology - a primer. Am J Cancer Res. 2021; 11 (4): 1121-1131
      [5] Golden Gate Cancer Center. Men with newly diagnosed prostate cancer – a primer. Available at:https://www.goldengatecancercenter.com/blog/men-with-newly-diagnosed-prostate-cancer-a-primer. Accessed January 2023.
      [6] European Federation of Pharmaceutical Industries and Associations. Precision Medicine. Availabe at: https://www.efpia.eu/about-medicines/development-of-medicines/precision-medicine/#:~:text=%E2%80%9CPrecision%20medicine%20is%20a%20healthcare,resulting%20in%20improved%20health%20outcomes%E2%80%9D. Accessed February 2023
      [7] ClinicalTrials.gov. A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE). Availabe at: https://clinicaltrials.gov/ct2/show/NCT03748641?term=niraparib++magnitude&draw=2&rank=1 Accessed February 2023
      [8] The Pharmaceutical Journal. The precision medicine approach to cancer therapy. Available at: https://pharmaceutical-journal.com/article/research/the-precision-medicine-approach-to-cancer-therapy-part-1-solid-tumours Accessed January 2023
      [9] John Hopkins. Prostate Cancer Prognosis. Available at: https://www.hopkinsmedicine.org/health/conditions-and-diseases/prostate-cancer/prostate-cancer-prognosis. Accessed January 2023
      [10] Cancer.net. Prostate Cancer: Statistics. Available at: https://www.cancer.net/cancer-types/prostate-cancer/statistics. Accessed January 2023
      [11] Seyhan, A.A., Carini, C. Are innovation and new technologies in precision medicine paving a new era in patients centric care?. J Transl Med 2019;17:114
      [12] American Association for Cancer Research. Intercepting Cancer by Tackling Precancer. Available at: https://www.aacr.org/blog/2021/01/15/intercepting-cancer-by-tackling-precancer/. Accessed January 2023
      [13] Clinicaltrials.gov. Molecular Studies and Clinical Correlations in Human Prostatic Disease. Available at: https://clinicaltrials.gov/ct2/show/NCT00578240. Accessed January 2023
      [14] Smith, R, M, et al. Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer. 2019; 18: 180-9
      [15] Carles, J. et al. ORACULUM. A Retrospective Observational Epidemiological Study Using Artificial Intelligence and Natural Language Processing in Electronic Health Records to Characterize the Prostate Cancer pathway, Management and Outcomes in Europe, Middle East and Africa (EMEA region). Poster presentation at the European Society for Medical Oncology Virtual Congress, September 2020 (abstract #695TiP).
      [16] Astex. Astex Announces New Drug Discovery Alliance with Janssen Pharmaceutica N.V. Available at: https://astx.com/wp-content/uploads/2016/11//ASTX_News_2008_6_9_General_Releases.pdf. Accessed January 2023
      [17] Ahuja AS. The impact of artificial intelligence in medicine on the future role of the physician. PeerJ. 2019;7:e7702.
      [18] MELLODDY. MELLODDY Project meets its year one objective: deployment of the world’s first secure platform for multi-task federated learning in drug discovery among 10 pharmaceutical companies. Available at: https://www.melloddy.eu/y1announcement. Accessed January 2023
      [19] WebMD. What Is B-Cell Lymphoma. Available at: https://www.webmd.com/cancer/lymphoma/what-is-b-cell-lymphoma. Accessed January 2023
      [20] Zhang, et al. Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis. Available at: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5924-6. Accessed January 2023
      [21] World Bladder Cancer Patient Coalition. Annual Meeting Report 2020. Available at: https://worldbladdercancer.org/wp-content/uploads/2020/11/WBCPC-Annual-Meeting-2020-Report.pdf. Accessed January 2023
      [22] Cancer.Net. Lung Cancer - Non-Small Cell: Statistics. Available at:https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. Accessed January 2023

      CP-459038
      September 2024